CAPRIcorn
Research type
Research Study
Full title
Cardiac Assessment of Patients Receiving Inhibitors of B-cell Receptor Signalling (CAPRIcorn)
IRAS ID
351833
Contact name
Stella Williams
Contact email
Sponsor organisation
The Clatterbridge Cancer Centre NHS Foundation Trust
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
This study aims to understand and predict cardiovascular side effects, such as high blood pressure and irregular heartbeats, in patients with chronic lymphocytic leukaemia (CLL) who are treated with specific drugs called Bruton’s tyrosine kinase inhibitors (BTKi). These drugs, such as ibrutinib and acalabrutinib, are effective for treating CLL but are known to cause heart-related side effects in some patients, which can affect their overall health and ability to continue treatment.
We will observe approximately 28 CLL patients over six months to address this issue to identify who may be at risk of developing these side effects. By regularly measuring heart rate, blood pressure, and specific blood biomarkers, and heart imaging, this study aims to create a profile of patients who may be more likely to experience these issues. This profile could help clinicians to more personalised treatment plans, potentially reducing the risk of heart-related problems and improving the safety of these therapies.
The study will take place at Clatterbridge Cancer Centre, where each participant will undergo a detailed heart health assessment at the beginning of their treatment and again after six months. By analysing these results, the research team hopes to develop tools to help healthcare providers predict and manage cardiovascular side effects more effectively.REC name
South Central - Hampshire B Research Ethics Committee
REC reference
25/SC/0050
Date of REC Opinion
24 Feb 2025
REC opinion
Further Information Favourable Opinion